Sands Capital Management
RARE icon

Sands Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sands Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Sell
3,158,368
-56,165
-2% -$1.4M 0.39% 47
2026
Q1 		$67.3M Sell
3,214,533
-271,191
-8% -$6.11M 0.26% 46
2025
Q4 		$80.2M Sell
3,485,724
-284,129
-8% -$9.34M 0.24% 48
2025
Q3 		$113M Sell
3,769,853
-173,632
-4% -$5.21M 0.31% 49
2025
Q2 		$143M Sell
3,943,485
-220,076
-5% -$7.93M 0.41% 42
2025
Q1 		$151M Sell
4,163,561
-134,442
-3% -$5.59M 0.51% 39
2024
Q4 		$181M Sell
4,298,003
-820,252
-16% -$40.7M 0.54% 39
2024
Q3 		$284M Sell
5,118,255
-236,495
-4% -$12M 0.86% 34
2024
Q2 		$220M Buy
5,354,750
+1,495,303
+39% +$63.8M 0.65% 37
2024
Q1 		$180M Sell
3,859,447
-258,561
-6% -$12.2M 0.5% 41
2023
Q4 		$197M Buy
4,118,008
+1,540,791
+60% +$59.7M 0.6% 40
2023
Q3 		$91.9M Sell
2,577,217
-96,421
-4% -$3.82M 0.31% 46
2023
Q2 		$123M Buy
+2,673,638
New +$124M 0.38% 46

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sands Capital Management's RARE Position: Q2 2026 in Review

Sands Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 1.7% in Q2 2026, selling an estimated $1.4M and leaving 3,158,368 shares worth $105M. The position accounts for 0.39% of the portfolio, ranked #47.

Sands Capital Management first reported a position in RARE in Q2 2023 and has held it in 13 quarters since. The position peaked at $284M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Sands Capital Management held 3,158,368 shares of Ultragenyx Pharmaceutical worth $105M as of Q2 2026.
  • Sands Capital Management sold 56,165 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.4M.
  • Ultragenyx Pharmaceutical made up 0.39% of Sands Capital Management's portfolio in Q2 2026, its #47 holding.
  • Sands Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • Sands Capital Management's Ultragenyx Pharmaceutical position peaked at $284M in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Sands Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.